Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments

June 30, 2022

Today, the U.S. Food and Drug Administration (FDA) issued a draft guidance, “Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments.” This guidance (Guidance 3) is the third in a series of guidance documents intended to facilitate the advancement and use of systematic approaches to collect and use robust and meaningful patient and caregiver input that can more consistently inform medical product development and regulatory decision-making. When final, this guidance will represent the current thinking of FDA’s Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, and Center for Devices and Radiological Health on this topic.

When final, the purpose of this guidance is to help sponsors identify or develop fit-for-purpose COA measures of patients’ health that are appropriate for use in a medical product development program.

Download the Final Guidance Document

Read the Federal Register Notice

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.




FDA North America

June 30, 2022

Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development; Draft Guidance for Industry; Availability

May 2022 Guidance Document Download the Final Guidance Document The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled “Use of...

Read More
Agency Alerts

June 30, 2022

FDA to Develop Standards for Safety Biomarker Qualification

On Thursday, February 25th, FDA announced plans to hold a public workshop to discuss the evidentiary standards necessary to support biomarker qualification. The workshop, entitled “Developing an...

Read More
FDA North America

June 30, 2022

Ulcerative Colitis: Developing Drugs for Treatment

Guidance Document April 2022. The purpose of this guidance is to help sponsors in the clinical development of drugs to treat adults with ulcerative colitis (UC). This guidance addresses the Food and...

Read More